De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells
Metrics: PDF 2945 views | HTML 3565 views | ?
Yi-Wen Chang1,*, Hsin-An Chen2,3,*, Chi-Feng Tseng1,4, Chih-Chen Hong1, Jui-Ti Ma1,4, Mien-Chie Hung5,6,7,8, Chih-Hsiung Wu2,3, Ming-Te Huang2,3 and Jen-Liang Su1,5,6,7
1 National Institute of Cancer Research, National Health Research Institutes, Zhunan, Miaoli Country, Taiwan
2 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
3 Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
4 Graduate Program of Biotechnology in Medicine College of Life Science, National Tsing Hua University, Hsinchu, Taiwan
5 Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan
6 Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
7 Department of Biotechnology, Asia University, Taichung, Taiwan
8 Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
* These authors contributed equally to this work
Jen-Liang Su , email:
Keywords: acetylation, adenovirus type 5 E1A, HSPA5/GRP78/Bip, metastasis, ubiquitination
Received: July 02, 2014 Accepted: September 24, 2014 Published: September 25, 2014
Elevated expression of heat shock protein 5 (HSPA5) promotes drug resistance and metastasis and is a marker of poor prognosis in breast cancer patients. Adenovirus type 5 E1A gene therapy has demonstrated antitumor efficacy but the mechanisms of metastasis-inhibition are unclear. Here, we report that E1A interacts with p300 histone acetyltransferase (HAT) and blocks p300-mediated HSPA5 acetylation at K353, which in turn promotes HSPA5 ubiquitination by GP78 (E3 ubiquitin ligase) and subsequent proteasome-mediated degradation. Our findings point out the Ying-Yang regulation of two different post-translational modifications (ubiquitination and acetylation) of HSPA5 in tumor metastasis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.